WO2000025827A2 - Dna molecules encoding muc-1 and use thereof in tumor vaccination - Google Patents
Dna molecules encoding muc-1 and use thereof in tumor vaccination Download PDFInfo
- Publication number
- WO2000025827A2 WO2000025827A2 PCT/EP1999/007874 EP9907874W WO0025827A2 WO 2000025827 A2 WO2000025827 A2 WO 2000025827A2 EP 9907874 W EP9907874 W EP 9907874W WO 0025827 A2 WO0025827 A2 WO 0025827A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- dna
- composition according
- fragment
- pharmaceutical composition
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title description 11
- 238000002255 vaccination Methods 0.000 title description 10
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims abstract description 99
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 11
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 9
- 239000002671 adjuvant Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 108020004414 DNA Proteins 0.000 claims description 92
- 239000013612 plasmid Substances 0.000 claims description 45
- 239000013604 expression vector Substances 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 108090000848 Ubiquitin Proteins 0.000 claims description 11
- 102000044159 Ubiquitin Human genes 0.000 claims description 11
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 1
- 108020005038 Terminator Codon Proteins 0.000 description 38
- 108010063954 Mucins Proteins 0.000 description 26
- 102000015728 Mucins Human genes 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 150000001413 amino acids Chemical group 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 238000010240 RT-PCR analysis Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010008707 Mucin-1 Proteins 0.000 description 3
- 102000007298 Mucin-1 Human genes 0.000 description 3
- 108091061960 Naked DNA Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 101100226904 Unknown prokaryotic organism FCS1 gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the invention relates to a pool of DNA plasmid constructs containing the sequences of human MUC-1 encoding fragments and to a pool of DNA plasmids in which the fragments themselves are preceded by the sequence encoding a protein consisting of human ubiquitin fused to a bacterial Lad fragment.
- the invention further relates to their use in the preparation of pharmaceutical compositions for use as DNA anti-tumor vaccines.
- the invention provides an anti-tumor therapy based on the induction or activation of the immune response able to bring about tumor rejection.
- the validity of such an idea is demonstrated from the first clinical results; for example, patients treated with a viral vaccine containing the Carcinoembryonic Antigen (CEA) encoding sequences demonstrated immune system activation against this antigen (Tsang KY et al . J. Natl. Cancer. Inst . 87: 982, 1995).
- CEA Carcinoembryonic Antigen
- an immune anti-tumor response is achievable through four different approaches: a) Ex vivo engineering of patient tumor cells in order to make them more immunogenic and suitable as a vaccine; b) Ex vivo engineering of patient immune cells in order to pre-activate an in vi tro immune response. c) Inoculation of naked or liposome capsulated or viral particle integrated (retrovirus, vaccinia virus, adenovirus, etc.) DNA encoding tumor associated antigens; d) Treatment with recombinant or synthetic soluble tumor antigens conjugated or mixed with adjuvants.
- the first two approaches consist of the engineering of every single patient cell and are limited in that they are necessarily patient-specific, while the latter two are aimed to obtain products comparable to a traditional drug.
- the new vaccination methods reflect the development of new technologies.
- Muscle cells express class I MHC antigens at low levels only, and do not apparently express class II antigens or co-stimulatory molecules. Consequently, transfected muscle cells are unlikely to play an important role in the onset of the immune response per se.
- Antigen Presenting Cells such as macrophages or dendritic cells
- APC Antigen Presenting Cells
- macrophages or dendritic cells play a fundamental role in capturing the myocyte released antigen and in the subsequent processing and presenting of the respective peptides in the context of the class I and II molecules, thus inducing a CD8+ cell activation with cytotoxic activity as well as activation of the CD4+ cells co-operating with B lymphocytes in eliciting the antibody response
- cytokines is known to improve the therapeutic effect deriving from immunization with DNA.
- Cytokines can be administered in the form of exogenous proteins as reported in Irvine et al . , J. Immunol . 156: 238, 1996.
- An alternative approach is represented by the contemporaneous inoculation of both the tumor antigen or the desired cytokine encoding plasmids, thus allowing the cytokine to be produced in si tu (Kim JJ et al . Immunol 158 : 816, 1997) .
- MUC-1 is an epithelial luminal surface glycoprotein (Patton S . et al . BBA 1241 : 407, 1995) . In the cell transformation process this glycoprotein loses the apical localization and its expression level rises dramatically.
- the protein function consists of protecting the luminal surfaces, for example in the mammal gland, ovary, endometrium, colon, stomach, pancreas, bladder, kidney, etc.
- a glycosylation defect is reported that makes tumor cell associated MUC-1 antigenically different from normal cell associated MUC-1. This phenomenon causes tumor MUC-1 to expose the antigen epitopes that are normally masked by the sugar moieties in the normal cell expressed MUC-1. This characteristic makes tumor MUC-1 particularly interesting in an induction of a tumor specific antibody response (Apostolopoulos V. et al . Cri t . Rev. Immunol . 14 :293, 1994) .
- the vaccination is aimed at inducing immune responses against tumor cells expressing MUC1 at high levels, preserving at the same time the low expressing normal epithelia.
- the DNA vaccination relies upon the entrance of a gene or portions thereof inside the body cells followed by transcription and translation of the inserted sequence and thus the intracellular synthesis of the corresponding polypeptide.
- An important advantage of this system is that the neo-synthesized protein is naturally processed inside the cell and the produced peptides are associated with the Major Histocompatibility Complex class I molecules (MHC-I) .
- MHC/peptide complexes are therefore naturally exported to the cell surface where they can be recognized by the immune system CD8+ cytotoxic cells.
- the invention relates particularly to a pharmaceutical composition containing one or more DNA encoding Mucin (MUC-1) protein fragments .
- the DNA used in the present invention can be plasmid or viral DNA, preferably plasmid DNA obtained employing the pMRS30 expression vector described in fig. 13.
- compositions according to the invention contain preferably at least two DNA fragments of the Mucin (MUC-1) or of another protein overexpressed in tumor cells.
- compositions according to the invention contain preferably at least four fragments, each ranging from 200 to about 700 nucleotides, each sequence being juxtaposed and possibly partially overlapping, from about 50 to about 150 nucleotides, at the 3' and/or 5' end of the adjacent one.
- the DNA fragments according to the invention can be possibly preceded at the 5' end by a ubiquitin encoding DNA sequence and possibly also by a Lad portion of Escherichia coli .
- the invention relates also to new DNA fragments and to the use of Mucin-1 fragments defined above in the medicine and anti- tumor vaccine preparation.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS166 expression vector.
- This DNA includes the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by the two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-339 fragment of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS169 expression vector.
- This DNA includes the sequence corresponding to nucleotides 205-720 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 205-720 fragment of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS168 expression vector.
- This DNA includes the sequence corresponding to nucleotides 631-1275 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 631-1275 fragment of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS167 expression vector.
- This DNA includes the sequence corresponding to nucleotides 1222-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 1222-1497 fragment of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS175 expression vector.
- This DNA includes the sequence corresponding to nucleotides 136-1497 of the EMBL sequence J05581, preceded by the translation start codon, ATG and followed by two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes a Metionin followed by the amino acids encoded by the 136-1497 fragment of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) termed UBILacI .
- the encoded polypeptide includes the ubiquitin sequence fused to a partial sequence of the bacterial protein beta-galactosidase, as described in Chau V. et al .
- Fig. 7 Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the expression vector pMRS30 to give the pMRS171 expression vector.
- This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA.
- the coded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-339 of the EMBL sequence J05581.
- Fig. 7 Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the expression vector pMRS30 to give the pMRS171 expression vector.
- This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence corresponding to nucleotides 136-339 of the EMBL sequence J05
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS174 expression vector.
- This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 205-720 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 205-720 of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS173 expression vector.
- This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 631-1275 of the EMBL sequence J05581 followed by two translation stop codons, TGA and
- the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 631-1275 of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS172 expression vector.
- This DNA includes the sequence termed UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 1222-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and
- the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 1222-1497 of the EMBL sequence J05581.
- Nucleotide DNA sequence (with the respective amino acid sequence) inserted at the Xbal site of the pMRS30 expression vector to give the pMRS176 expression vector.
- This DNA includes the sequence named UBILacI (see fig. 6) fused to the sequence partially corresponding to nucleotides 136-1497 of the EMBL sequence J05581 followed by two translation stop codons, TGA and TAA.
- the encoded polypeptide thus includes the amino acid sequence reported in Fig. 6, fused to the sequence including the amino acids encoded by the fragment 136-1497 of the EMBL sequence J05581.
- the 1- 2862 region corresponds to the Accl (location 504) - BamHI (location 3369) region of the pSV2CAT vector (EMBL M77788) ;
- the 2863-3721 region includes the human cytomegalovirus promoter (human cytomegalovirus major immediate-early gene enhancer) ;
- the 3722-4905 region includes several cloning sites, including Xbal (location 3727) , and the processing signal of the rabbit beta- globin gene.
- a DNA plasmid pool encoding, in eukaryotic cells, fragments of the MUC-1 human protein antigen was prepared. Constructs are based on the mammalian expression vector termed pMRS30, described in figure 13 and previously claimed in the Patent Application W095/11982, and contain partial sequences of the MUC-1 cDNAs reported in the EMBL database with accession number J05581. MUC-1 encoding DNA was fragmented so that each fragment represents a discrete portion, partially overlapping to the adjacent ones. Administration of a mix of such plasmids can cause different plasmids to transfect different APC cells at the administration site. Therefore such cells produce and process discrete portions of the MUC-1 protein giving the related peptides.
- the occurring subdominant and cryptic peptides can also be presented in association with class I MHC molecules thus generating a cytotoxic immune response.
- the present invention thus relates to the use of a group of four constructs ( Figures 1 to 4) containing MUC-1 cDNA partial fragments in admixture containing at least two of them and a group of four constructs ( Figures 7 to 10) containing MUC-1 cDNA partial fragment preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion ( Figure 6) used separately or in admixture containing at least two of them.
- the present invention relates also to the use of the construct ( Figure 5) containing the almost complete sequence of the MUC-1 cDNA and the construct ( Figure 11) containing the almost complete sequence of the MUC-1 cDNA preceded by the DNA encoding a protein sequence containing Ubiquitin and an Escherichia coli Lac I portion.
- the mixture of the four constructs containing the partial fragments of the MUC-1 cDNA and the mixture of the four constructs containing the partial fragments of the MUC-1 cDNA preceded by the DNA encoding a protein sequence, containing Ubiquitin and an Escherichia coli Lac I portion, represents a preferred embodiment of the present invention.
- Constructs according to the present invention can be used in the anti-tumor therapy of patient affected with tumors characterized by high MUC-1 expression.
- Constructs described in the present invention were obtained as follows.
- the fragments of the MUC-1 DNA were obtained by RT-PCR from BT20 cell line or by DNA partial chemical synthesis. Such fragments were then cloned into the pMRS30 expression vector and verified by sequencing.
- the fragments were obtained from the first series of constructs by a PCR re-amplification. These fragments were then fused to the DNA encoding the Ubiquitin (obtained by RT-PCR from MCF7 cell line mRNA) and a partial lad sequence (obtained by PCR from the commercial vector pGEX) .
- fragments or constructs according to the invention are suitably formulated, using carriers and methods previously employed in naked DNA vaccines, as described for example in The Immunologist, 1994, 2:1; WO 90/11092, Proc . Natl. Acad. Sci . U.S.A., 1986, 83, 9551; US 5580859; Immunology today 19 (1998), 89-97); Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 11478-11482; Nat. Med. 3 (1997), 526-532; Vaccine 12 (1994), 1495-1498; DNA Cell. Biol.
- the dosages will be determined on the basis of clinical and pharmacological-toxicological trials. Generally speaking, they will be comprised between 0.005 ⁇ g/kg and 5 ⁇ g/kg of the fragment mix.
- the composition of the invention can also contain a cytokine or a cytokine encoding plasmid.
- Example 1 Plasmid pMRSl ⁇ construction.
- BT20 tumor cells (ATCC HTB-19) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.
- RNA was subjected to RT-PCR (reverse transcriptase-polymerase chain reaction) reaction in the presence of the following synthetic oligonucleotides :
- VI1 (5 GATCTCTAGAATGACAGGTTCTGGTCATGCAAGC 3)
- V4 (5 GATCTCTAGAAAGCTTATCAACCTGAAGCTGGTTCCGTGGC 3)
- the resulting pMRS166 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 136-339 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
- RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides :
- the whole fragment was thus cloned in the Xbal site of the pMRS30 expression vector.
- the resulting pMRS169 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 205-720 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
- RNA obtained as reported in example 1 was amplified by RT-PCR in the presence of the following synthetic oligonuclotides :
- VI3 (5 GATCTCTAGAATGGGCTCAGCTTCTACTCTGGTGCACAACGGC 3)
- V8 (5 GATCTCTAGAAAGCTTATCACAAGGCAATGAGATAGACAATGGCC 3)
- the produced DNA fragment, purified and digested with the restriction enzyme Xbal was cloned in the pMRS30 expression vector.
- the resulting pMRS168 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 631-1275 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
- Example 4 Plasmid pMRS167 construction. An aliquot of the RNA obtained as reported in example 1 was subjected to RT-PCR reaction in the presence of the following synthetic oligonucleotides :
- the produced DNA fragment, purified and digested with the restriction enzyme Xbal was cloned in the pMRS30 expression vector.
- the resulting pMRS167 vector contains a DNA fragment including the ATG codon, the sequence corresponding to the nucleotides 1222-1497 of the EMBL sequence J05581, and two stop codons, TGA and TAA.
- Example 5 Plasmid pMRS175 construction. pMRS166, 169, 168, 167 plasmids were subjected to PCR reaction in the presence of the following nucleotide pairs: VI1 (see example 1)
- V21 (5 GGCTCAGCTTCTACTCTGGTGCACAACGGC 3)
- V22 (5 CAAGGCAATGAGATAGACAATGGCC 3) for pMRS168
- V23 (5 CTGGTGCTGGTCTGTGTTCTGGTTGCG 3)
- the four DNA fragments obtained in the respective PCR reactions were mixed in equimolar amounts and PCR reacted in the presence of the Vll and V10 oligonuclotides.
- the resulting pMRS175 vector contains a DNA fragment including the ATG codon, the sequence partially corresponding to the nucleotides 136-1497 of the EMBL sequence J05581 and two stop codons TGA and TAA.
- Example 6 Plasmid pMRS171 construction.
- MCF7 tumor cells (ATCC HTB-22) were cultured in Eagles MEM supplemented with 10% fetal calf serum. Ten million cells were trypsinized, washed with PBS, and mRNA extracted.
- DNA from pGEXHT (Pharmacia) was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
- LacIdown (5GATCGGATCCTCGGGAAACCTGTCGTGCCAGCTGC 3) This reaction gives a DNA fragment termed fragment 2.
- the resulting pMRS156 vector contains a DNA fragment including the sequence encoding the ubiquitin fused to the sequence encoding a bacterial beta-galactosidase portion. This fragment, termed UBILacI, is reported in fig. 6.
- Plasmid pMRS166 DNA was subjected to a PCR reaction in presence of the following synthetic oligonucleotides: V3 (5GATCGGATCCACAGGTTCTGGTCATGCAAGC 3) V4 (see Example 1)
- V3 5GATCGGATCCACAGGTTCTGGTCATGCAAGC 3
- V4 see Example 1
- the resulting fragment was cloned into the pMRS30 expression vector.
- the resulting pMRS171 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-339 nucleotides of the EMBL sequence J05581 and two stop codons, TGA and TAA. This fragment is reported in fig. 7.
- Plasmid pMRS174 construction Plasmid pMRS169 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides: V5 (5GATCGGATCCGTGCCCAGCTCTACTGAGAAGAATGC 3) V6 (5GATCTCTAGAAAGCTTATCAGCTGGGAATTGAGAATGGAGTGCTCTTGC 3) The produced DNA fragment, purified and digested with the restriction enzymes Xbal and BamHI, was fused, by ligation into the two BamHI sites, to the UBILacI fragment deriving from the pMRS156 plasmid. The resulting fragment was cloned into the pMRS30 expression vector.
- the resulting pMRS174 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 205-720 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 8.
- Plasmid pMRS168 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
- V7 (5GATCGGATCCGGCTCAGCTTCTACTCTGGTGCACAACGGC 3)
- V8 (see example 3)
- the resulting fragment was cloned into the pMRS30 expression vector.
- the resulting pMRS173 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 631-1275 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 9.
- Plasmid pMRS167 DNA was subjected to PCR reaction in the presence of the following synthetic oligonucleotides:
- the resulting fragment was cloned into the pMRS30 expression vector.
- the resulting pMRS172 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 1222-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 10.
- Plasmid pMRS167 DNA was subjected PCR reaction in the presence of the following synthetic oligonucleotides: V3 (see example 6)
- the resulting fragment was cloned into the PMRS30 expression vector.
- the resulting pMRS176 vector contains a DNA fragment including the UBILacI sequence, the sequence corresponding to the 136-1497 nucleotides of the EMBL sequence J05581, and two stop codons, TGA and TAA. This fragment is reported in fig. 11.
- Example 11 Eukaryotic cell transfection and testing for transcriptio .
- CHO (Chinese Hamster Ovary) cells were cultured in alpha MEM supplemented with ribonucleotides and deoxyribonucleotides at transfection time.
- Dendritic cells were obtained from CD34+ hemopoietic precursors cultured in IMDM without serum, supplemented with GM- CSF, IL4, SCF, Fit3 and TNFalpha. After 7 days the obtained cell population was transfected.
- Dendritic cells were obtained from monocytes isolated from PBMC (peripheral blood mononuclear cells) , cultured in RPMI supplemented with FCS, GM-CSF, and IL-4. After 7 days the obtained cell population was transfected. In each case, about one million cells were transfected with one of the plasmids reported in examples 1 to 10. Transfection was carried out using 3 ⁇ g of plasmid DNA and 4 ⁇ l of DMRIE (Gibco) by lipofection.
- a mRNA aliquot was subjected to RT-PCR reaction in the presence of the oligonucleotide pair specific for the transfected DNA plasmid.
- figure 12 reports the electrophoretic analysis of the DNA fragments obtained by RT-PCR from the mRNA of the three cell populations, transfected with the pMRS169 plasmid. In this case the oligonucleotide pair V12/V6 was used. Example 12. In vivo study results.
- the in vivo studies were conducted using human MUCl transgenic C57BL mice. As a consequence in these animals the MUCl protein represents a self-protein.
- the employed vaccination schedule consists of 3 intradermic (dorsal portion, 50 micrograms DNA for each side) administrations (at days 0, 14, 28) of 100 micrograms plasmid DNA. At day 14 after the last administration, the animals were sacrificed and sera were tested for anti-human mucin antibodies. The assayed fragment mixes, object of the present invention, stimulated a good immune response in the treated animals.
- the two vaccinations differ in the type of the elicited antibody response.
- the antibody titer results much more higher in the vaccination with 3XTR.
- IgG subtypes are in favor of an essentially humoral (antibody) response in the case of vaccination with 3XTR, and of a cellular response (cytotoxic) in the case of vaccination with DNA.
- cytotoxic a principally cytotoxic immune response is preferable. Because the experiments were carried out on transgenic mice, in whom the human mucin is "self", we can foresee a similar response in humans. This response could justify the use, as DNA vaccines, of the compounds of the present invention in the treatment of MUCl overxpressing human tumors .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA01004186A MXPA01004186A (es) | 1998-10-30 | 1999-10-18 | Composicion farmaceutica, que contiene fragmentos de acido de desoxirribonucleico que codifica una proteina antigenica con efecto anti-tumoral. |
CA002348745A CA2348745A1 (en) | 1998-10-30 | 1999-10-18 | Dna molecules encoding muc-1 and use thereof in tumor vaccination |
BR9914892-7A BR9914892A (pt) | 1998-10-30 | 1999-10-18 | Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor |
JP2000579265A JP2002528519A (ja) | 1998-10-30 | 1999-10-18 | 抗腫瘍効果を有する、抗原性タンパク質をコードしているdnaを含む医薬組成物 |
EA200100395A EA200100395A1 (ru) | 1998-10-30 | 1999-10-18 | Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием |
HU0103784A HUP0103784A2 (hu) | 1998-10-30 | 1999-10-18 | MUC-1-et kódoló DNS molekulák és ezek alkalmazása tumorellenes vakcinálásban |
PL99348156A PL348156A1 (en) | 1998-10-30 | 1999-10-18 | Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect |
SK571-2001A SK5712001A3 (en) | 1998-10-30 | 1999-10-18 | Pharmaceutical composition |
EP99971329A EP1124956A2 (en) | 1998-10-30 | 1999-10-18 | Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect |
AU11522/00A AU1152200A (en) | 1998-10-30 | 1999-10-18 | Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect |
BG105458A BG105458A (en) | 1998-10-30 | 2001-04-20 | Dna molecules encoding muc-1 and use thereof in tumor vaccination |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1998MI002330A IT1303683B1 (it) | 1998-10-30 | 1998-10-30 | Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica. |
ITMI98A002330 | 1998-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000025827A2 true WO2000025827A2 (en) | 2000-05-11 |
WO2000025827A3 WO2000025827A3 (en) | 2000-08-10 |
Family
ID=11380969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/007874 WO2000025827A2 (en) | 1998-10-30 | 1999-10-18 | Dna molecules encoding muc-1 and use thereof in tumor vaccination |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1124956A2 (it) |
JP (1) | JP2002528519A (it) |
CN (1) | CN1324406A (it) |
AR (1) | AR020927A1 (it) |
AU (1) | AU1152200A (it) |
BG (1) | BG105458A (it) |
BR (1) | BR9914892A (it) |
CA (1) | CA2348745A1 (it) |
CO (1) | CO5231134A1 (it) |
CZ (1) | CZ20011521A3 (it) |
EA (1) | EA200100395A1 (it) |
HU (1) | HUP0103784A2 (it) |
IT (1) | IT1303683B1 (it) |
MX (1) | MXPA01004186A (it) |
PE (1) | PE20001287A1 (it) |
PL (1) | PL348156A1 (it) |
SK (1) | SK5712001A3 (it) |
TR (1) | TR200101141T2 (it) |
WO (1) | WO2000025827A2 (it) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
WO2002022685A3 (en) * | 2000-09-11 | 2002-09-26 | Donald W Kufe | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
WO2005042573A1 (en) * | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
US7696306B2 (en) * | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
US7745109B2 (en) | 2000-12-22 | 2010-06-29 | Dana-Farber Cancer Insitute, Inc. | Regulation of cell growth by MUC1 |
US7871784B2 (en) | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1622648T3 (da) * | 2003-03-24 | 2010-09-06 | Scripps Research Inst | DNA-vacciner mod tumorvækst og fremgangsmåder til anvendelse deraf |
CN106279435B (zh) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 |
CN114230655A (zh) * | 2021-03-24 | 2022-03-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011982A1 (en) * | 1993-10-25 | 1995-05-04 | Menarini Ricerche Sud S.P.A. | Expression system for eukaryotic cell lines |
WO1998037095A2 (en) * | 1997-02-24 | 1998-08-27 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-10-30 IT IT1998MI002330A patent/IT1303683B1/it active
-
1999
- 1999-10-18 TR TR2001/01141T patent/TR200101141T2/xx unknown
- 1999-10-18 HU HU0103784A patent/HUP0103784A2/hu unknown
- 1999-10-18 EA EA200100395A patent/EA200100395A1/ru unknown
- 1999-10-18 PL PL99348156A patent/PL348156A1/xx unknown
- 1999-10-18 JP JP2000579265A patent/JP2002528519A/ja active Pending
- 1999-10-18 CA CA002348745A patent/CA2348745A1/en not_active Abandoned
- 1999-10-18 WO PCT/EP1999/007874 patent/WO2000025827A2/en not_active Application Discontinuation
- 1999-10-18 MX MXPA01004186A patent/MXPA01004186A/es unknown
- 1999-10-18 EP EP99971329A patent/EP1124956A2/en not_active Withdrawn
- 1999-10-18 AU AU11522/00A patent/AU1152200A/en not_active Abandoned
- 1999-10-18 BR BR9914892-7A patent/BR9914892A/pt not_active IP Right Cessation
- 1999-10-18 CN CN99812745A patent/CN1324406A/zh active Pending
- 1999-10-18 SK SK571-2001A patent/SK5712001A3/sk unknown
- 1999-10-18 CZ CZ20011521A patent/CZ20011521A3/cs unknown
- 1999-10-21 AR ARP990105316A patent/AR020927A1/es unknown
- 1999-10-22 PE PE1999001068A patent/PE20001287A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068636A patent/CO5231134A1/es not_active Application Discontinuation
-
2001
- 2001-04-20 BG BG105458A patent/BG105458A/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011982A1 (en) * | 1993-10-25 | 1995-05-04 | Menarini Ricerche Sud S.P.A. | Expression system for eukaryotic cell lines |
WO1998037095A2 (en) * | 1997-02-24 | 1998-08-27 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
Non-Patent Citations (8)
Title |
---|
ANTON ET AL: "MHC CLASS I-ASSOCIATED PEPTIDES PRODUCED FROM ENDOGENOUS GENE PRODUCTS WITH VASTLY DIFFERENT EFFICICIENCES" THE JOURNAL OF IMMUNOLOGY, vol. 158, 1997, pages 2535-2542, XP002136996 cited in the application * |
CHAU V ET AL: "A MULTIUBIQUITIN CHAIN IS CONFINED TO SPECIFIC LYSINE IN A TARGETED SHORT-LIVED PROTEIN" SCIENCE (WASHINGTON D C) 1989, vol. 243, no. 4898, 1989, pages 1576-1589, XP002136993 ISSN: 0036-8075 cited in the application * |
GENDLER S J ET AL: "MOLECULAR CLONING AND EXPRESSION OF HUMAN TUMOR-ASSOCIATED POLYMORPHIC EPITHELIAL MUCIN" JOURNAL OF BIOLOGICAL CHEMISTRY 1990, vol. 265, no. 25, 1990, pages 15286-15293, XP002136995 ISSN: 0021-9258 * |
GRAHAM R A ET AL: "The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine" CANCER IMMUNOLOGY AND IMMUNOTHERAPY,DE,BERLIN, vol. 2, no. 42, 1 January 1996 (1996-01-01), pages 71-80, XP002075466 ISSN: 0340-7004 * |
GRANT ETHAN P ET AL: "Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation." JOURNAL OF IMMUNOLOGY 1995, vol. 155, no. 8, 1995, pages 3750-3758, XP002136994 ISSN: 0022-1767 cited in the application * |
RODRIGUEZ FERNANDO ET AL: "DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction." JOURNAL OF VIROLOGY 1997, vol. 71, no. 11, 1997, pages 8497-8503, XP002136992 ISSN: 0022-538X cited in the application * |
See also references of EP1124956A2 * |
TAYLOR-PAPADIMITRIOU J AND EPENETOS A A: "Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy" TIBTECH,GB,CAMBRIDGE, no. 12, 1 January 1994 (1994-01-01), pages 227-233, XP002075467 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
WO2002022685A3 (en) * | 2000-09-11 | 2002-09-26 | Donald W Kufe | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
US7745109B2 (en) | 2000-12-22 | 2010-06-29 | Dana-Farber Cancer Insitute, Inc. | Regulation of cell growth by MUC1 |
US7696306B2 (en) * | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
US8193309B2 (en) | 2003-07-11 | 2012-06-05 | Board Of Regents Of The University Of Nebraska | Compositions and methods for preventing or treating cancer |
US8653233B2 (en) | 2003-07-11 | 2014-02-18 | University Of Nebraska Medical Center | Compositions and methods for preventing or treating cancer |
WO2005042573A1 (en) * | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
US7871784B2 (en) | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
Also Published As
Publication number | Publication date |
---|---|
EP1124956A2 (en) | 2001-08-22 |
BG105458A (en) | 2002-06-28 |
PE20001287A1 (es) | 2000-12-07 |
IT1303683B1 (it) | 2001-02-23 |
WO2000025827A3 (en) | 2000-08-10 |
EA200100395A1 (ru) | 2001-10-22 |
CA2348745A1 (en) | 2000-05-11 |
ITMI982330A1 (it) | 2000-04-30 |
TR200101141T2 (tr) | 2001-09-21 |
PL348156A1 (en) | 2002-05-06 |
CZ20011521A3 (cs) | 2001-10-17 |
HUP0103784A2 (hu) | 2002-02-28 |
BR9914892A (pt) | 2001-07-17 |
AR020927A1 (es) | 2002-06-05 |
JP2002528519A (ja) | 2002-09-03 |
ITMI982330A0 (it) | 1998-10-30 |
MXPA01004186A (es) | 2002-06-04 |
CN1324406A (zh) | 2001-11-28 |
AU1152200A (en) | 2000-05-22 |
SK5712001A3 (en) | 2002-04-04 |
CO5231134A1 (es) | 2002-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7446185B2 (en) | Her2/neu target antigen and use of same to stimulate an immune response | |
Tüting et al. | Gene-based strategies for the immunotherapy of cancer | |
EP1658097B1 (en) | Nucleotide and cellular vaccine composition | |
Schultz et al. | Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA | |
EP2041287B1 (en) | Methods for effectively coexpressing il-12 and il-23 | |
Kim et al. | Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine | |
WO2019101062A9 (zh) | 重组疫苗及其应用 | |
EP1124956A2 (en) | Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect | |
KR101810840B1 (ko) | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) | |
RU2303069C2 (ru) | Антиген muc1 со сниженным числом повторяющихся vntr-блоков | |
Restifo et al. | Enhancing the recognition of tumor associated antigens | |
AU776795B2 (en) | Chorionic gonadotropin DNA vaccines and methods | |
Santin et al. | Development and characterization of an IL-4-secreting human ovarian carcinoma cell line | |
US20070042047A1 (en) | Vaccines | |
US20060062798A1 (en) | Vaccines | |
WO1998015285A9 (en) | Methods and compositions for inducing a protective immune response to cancers | |
Clary et al. | Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system | |
CA2460809A1 (en) | Polynucleotide vaccine | |
Moelling et al. | Development of a DNA Vaccine Againts Malignant Melanoma | |
JP2010502176A (ja) | 合成遺伝子 | |
MXPA99012024A (en) | Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment | |
AU2002244196A1 (en) | Tri-hybrid melanoma antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99812745.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 11522 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 1999 105458 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/004186 Country of ref document: MX Ref document number: 2001/01141 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2348745 Country of ref document: CA Ref document number: 2348745 Country of ref document: CA Kind code of ref document: A Ref document number: 2000 579265 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09830513 Country of ref document: US Ref document number: 5712001 Country of ref document: SK Ref document number: IN/PCT/2001/591/CHE Country of ref document: IN Ref document number: 1999971329 Country of ref document: EP Ref document number: PV2001-1521 Country of ref document: CZ Ref document number: 200100395 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1999971329 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1521 Country of ref document: CZ |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-1521 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999971329 Country of ref document: EP |